Key Takeaways Oppenheimer analysts on Thursday said that given this week's tariff news, they prefer defensive consumer stocks ...

As interest rates fall, business development companies', or BDCs, return on equity will likely be pressured. Oppenheimer ...

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative ...

Nolan is writing the script and producing the film alongside his wife, Emma Thomas, through their production company, Syncopy ...

Oppenheimer raised the firm’s price target on AT&T to $32 from $27 and keeps an Outperform rating on the shares. The firm cites better free ...

Robert Downey Jr is celebrating his 60th birthday on April 4, 2025. The Hollywood actor, best known for his role as Iron Mon, ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Biomea Fusion (BMEA – Research Report), with a price ...

Oppenheimer expects S&P 500 to bounce back a little in April. The investment firm warns the bounce could prove short lived.

Christopher Nolan’s Oppenheimer was that rare movie that was both a box office hit and a serious award winner. It also had one of the most incredibly stacked casts in recent memory. Jack Quaid ...

A popular theory frequently utilized by technical analysts suggests U.S. stocks could be headed for one last leg higher over ...

Oppenheimer maintained its Outperform rating on AppLovin (APP) while highlighting key points for the company from the ...